Engflag

Ambroxol/Benzonatate

Quick links to important sections

Ambroxol/Benzonatate

Ambroxol_Benzonatate_EN

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ambroxol/Benzonatate

Property Description
Active Ingredients Ambroxol, Benzonatate
Form Oral dosage forms (e.g., capsule, tablet, syrup)
Pharmacological Class Mucolytic Agent, Antitussive Agent
Common Use Symptomatic relief of cough and mucus congestion
Origin Synthetic Organic

Ambroxol/Benzonatate is defined as a fixed-dose combination drug that employs a dual pharmacological strategy, integrating a mucolytic agent and an antitussive agent into one preparation. This synthetic organic medicine is administered orally, available in several forms including capsules, tablets, and syrup. The combination is distinguished by its unique approach to managing two primary respiratory symptoms simultaneously, which is supported by pharmacological studies demonstrating the complementary mechanisms of its components.

The Roles of Ambroxol and Benzonatate in Composition

The preparation contains two distinct active ingredients: Ambroxol and Benzonatate. Ambroxol functions as a secretolytic and mucoactive agent that is clinically recognized for its ability to thin thick, viscid mucus and enhance surfactant production. This action helps make phlegm less sticky and easier to clear from the airways. Conversely, Benzonatate is a non-narcotic antitussive. This component provides a local anesthetic effect by desensitizing the stretch receptors in the respiratory passages, which are responsible for triggering the cough reflex. This peripheral action means Benzonatate specifically targets the physical sensation that provokes an irritating cough.

General Therapeutic Purpose

The overall therapeutic purpose of this combination drug is to offer integrated symptomatic relief by addressing both the mechanical irritation and the persistent reflexive cough. The medication is positioned for use when a patient presents with both a persistent cough and difficulty clearing thick secretions. This dual benefit is fundamental to its design, combining Benzonatate's ability to suppress the cough signal with Ambroxol's role in improving mucociliary action for efficient clearance and enhancing general respiratory comfort.

What side effects are possible with Ambroxol/Benzonatate?

Possible Side Effects and Safety Information

The officially documented safety profile for the components Ambroxol and Benzonatate is characterized by the classification of adverse reactions into frequency categories and affected system-organ classes, as defined by government regulatory authorities.

Adverse Reaction Classification

Side effects for the Ambroxol component are frequently classified, often listing gastrointestinal and nervous system effects. The most Common reactions reported include taste disturbance (dysgeusia), nausea, and oral numbness (oral hypoaesthesia). Less frequent, or Uncommon, effects may involve vomiting, diarrhea, abdominal pain, and dry mouth. The Benzonatate component is associated with general reactions such as headache, dizziness, and somnolence.

Serious Adverse Reactions

The regulatory documentation highlights the potential for rare but serious adverse reactions. For Ambroxol, these include severe cutaneous adverse reactions (SCARs), such as Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), and severe allergic reactions like anaphylactic shock and angioedema. The Benzonatate component carries a specific safety risk related to administration: chewing or sucking the capsule can cause rapid local anesthesia and lead to potentially fatal systemic effects, including circulatory collapse and respiratory arrest.

Population-Specific Safety Considerations

Official labels include specific safety notes for certain patient populations. Caution is advised when Ambroxol is used in individuals with severe renal or hepatic impairment due to the potential for metabolite accumulation. Furthermore, the FDA label specifies that Benzonatate is not approved for use in children under 10 years of age due to the established risk of fatal overdose. Treatment with Ambroxol requires immediate discontinuation if any new skin or mucosal lesions appear.

These safety classifications and constraints define the official risk structure for the medicine, distinguishing less frequent or expected effects from rare, critical safety events.

Overdose and Emergency Response

Overdose Map: Overdose and when to seek help — Official Regulatory Information for Ambroxol/Benzonatate

Overdose Scope

Category Officially Documented Regulatory Statements
Documented overdose presentations Initial CNS stimulation (restlessness, tremors) progressing to profound CNS depression, convulsions (seizures), coma, mental confusion, and visual hallucinations. Gastrointestinal effects include nausea, vomiting, diarrhea, abdominal pain, and excessive saliva secretion.
Physiological systems affected (as stated in label) Central Nervous System, Cardiovascular System, Respiratory System, Gastrointestinal System.
Dose-related or exposure-related factors (if applicable) Overdose has been reported in children following accidental ingestion of as few as one or two capsules. Onset of severe symptoms can occur rapidly, often within 15 to 20 minutes of ingestion.
Population-specific overdose notes (if applicable) Accidental ingestion in children below age 10 can result in death from overdose. In patients with severe renal insufficiency, accumulation of hepatic metabolites should be expected.
Emergency-response statements (as written in official documents) Treatment should be mainly symptomatic and supportive. Convulsions should be treated with a short-acting barbiturate administered intravenously. Intensive support of respiration and cardiovascular-renal function is essential.
When immediate medical help is required (label-derived phrasing only) Seek medical attention immediately in case of overdose or accidental ingestion. Immediate medical advice must be sought if a progressive skin rash (associated with blisters or mucosal lesions) is present.

Overdose Classifications (High-Level)

Category Officially Documented Regulatory Statements
Severity classification (as defined in official documents) Life-threatening (associated with cardiac arrest, cerebral edema, and death), Severe Toxicity.
Regulatory basis (EMA / FDA / etc.) FDA Prescribing Information, FDA Safety Communications, SmPC documents.
Overdose-context constraints (as defined in official documents) No specific antidote is known for the mucolytic component. Gastric lavage is not generally indicated but can be considered within the first two hours in cases of very high overdose.

Resulting Overdose Structure

Official overdose statements:

  • Overdose may present with CNS stimulation followed by depression, including the manifestation of convulsions, coma, and abnormal heart rhythms.
  • Cardiac arrest and death are officially documented severe outcomes, particularly following accidental ingestion by children below age 10.
  • Regulators mandate that patients seek medical attention immediately following any suspected overdose or accidental ingestion due to the rapid onset of toxicity.
  • Treatment is primarily symptomatic and supportive, with no specific antidote known for the Ambroxol component.
  • Specific supportive measures include treating convulsions with an administered short-acting barbiturate and ensuring intensive support of respiration and cardiovascular function.

Connection to the overall overdose profile (2–4 sentences): The regulatory documents define the overdose profile by linking rapid, potentially fatal neurotoxicity and cardiac effects primarily to the antitussive component. This profile establishes that the symptoms, which include both CNS stimulation and profound depression, require that urgent, immediate medical attention be sought to manage life-threatening outcomes such as cardiac arrest. The official guidance emphasizes symptomatic and supportive care due to the absence of a specific antidote for the mucolytic component.

Therapeutic Uses of Ambroxol/Benzonatate

What Ambroxol/Benzonatate Treats: Main Uses and Benefits

Integrated Support for Respiratory Symptoms

The Ambroxol/Benzonatate combination is commonly used across conditions where symptoms cluster into patterns of both a troublesome cough and accompanying mucus congestion. This combination is relevant in contexts involving heightened systemic burden from respiratory illnesses. The primary therapeutic domain of the combination is the supportive relief of these co-occurring symptomatic manifestations.

The antitussive component is used to relieve cough, while Ambroxol, the mucolytic agent, is applied in addressing respiratory diseases associated with viscid or excessive mucus. The medication is generally applied in scenarios where short-term symptomatic assistance is needed.

Managing Cough and Secretions

The combination is commonly used to help with symptoms arising from conditions such as acute bronchitis, symptomatic episodes of the common cold, and influenza. This medication is relevant for easing symptoms linked to organ-specific functional stress caused by thick secretions and persistent irritation. By modulating the persistent cough reflex, the combination provides supportive relief that contributes to improved comfort during periods of heightened symptoms. The combination plays a role in managing symptoms related to heightened physiological activity, specifically the frequent and fatiguing cough reflex, and the difficulty in clearing viscid mucus.

Quick Fact: Relief for Dual Discomfort
Supports easing the overall symptom load related to cough and congestion in conditions characterized by periods of heightened symptoms.

Regulatory References

  1. MedlinePlus Drug Information

Eligibility and Restrictions for Use

Eligibility for Ambroxol/Benzonatate: Official Regulatory Information

The eligibility profile for the Ambroxol/Benzonatate combination is strictly defined by regulatory authorities to ensure appropriate use.

Classification Population/Condition
Absolute Contraindication Children under 10 years of age
Absolute Contraindication Known hypersensitivity to Ambroxol, Benzonatate, or related local anesthetics (PABA-analogs)
Not Recommended Pregnant women, particularly during the first trimester
Not Recommended Breastfeeding women

Use of this medicine is generally allowed for adults and adolescents 10 years of age and older. However, special caution and conditional use are required for patients with severe hepatic disease (liver impairment) or impaired renal function (kidney disease). The restrictions on use in children under 10 are based on regulatory safety concerns associated with the Benzonatate component. Conditional use is also necessary for patients with certain rare hereditary conditions that may be incompatible with the excipients in specific formulations.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Regulatory documents define several interaction patterns for the Ambroxol/Benzonatate combination, primarily involving pharmacodynamic conflicts and effects on drug exposure.

Pharmacodynamic Restrictions: Co-administration with other antitussives (cough suppressants) is not recommended. This restriction is due to a functional conflict: the Ambroxol component increases mucus production while the concurrent antitussive suppresses the necessary cough reflex, leading to the risk of secretion retention and potential airway obstruction. Furthermore, the Benzonatate component exhibits additive pharmacodynamic reinforcement with Central Nervous System (CNS) depressants, including opioids, sedatives, and alcohol, which may enhance dizziness and sedation. Official regulatory caution also applies to co-administering with local anesthetic agents due to shared chemical properties and the risk of serious adverse effects.

Exposure and Clearance: A specific pharmacokinetic interaction is documented where the Ambroxol component causes an increase in the concentration of certain antibiotics (Amoxicillin, Cefuroxime, Erythromycin, Doxycycline) in lung tissue and bronchial secretions. Additionally, regulatory labeling includes population-specific interaction notes for individuals with severe renal or hepatic impairment, where reduced clearance of Ambroxol is expected, leading to a risk of metabolite accumulation. No mandatory timing or separation rules are specified for administering this product with other medications.

Mechanism of Action

How Ambroxol/Benzonatate Works

Ambroxol and Benzonatate function through distinct, yet complementary, mechanistic domains to modulate the respiratory system's physiology.

Modulation of Airway Clearance

This domain involves Ambroxol's role as a mucoactive agent. It acts on the pulmonary system to stimulate the synthesis and release of surfactant by pneumocytes, which helps thin and break down acid mucopolysaccharide fibers in mucus. This facilitates the transport and clearance of respiratory secretions. The net result is increased rate of mucociliary transport.

Peripheral Sensory Nerve Desensitization

This domain centers on Benzonatate's local anesthetic-like effect, primarily mediated by the blockade of neuronal sodium channels (like Nav1.7). This action desensitizes the stretch receptors located in the respiratory passages, lungs, and pleura. The net result is a dampened afferent signal to the medullary cough center.

Anti-inflammatory Pathway Effects

Ambroxol also influences systemic regulatory pathways. It engages mechanisms to reduce the release of pro-inflammatory cytokines and other mediators, while exhibiting antioxidant activity. This action results in the downstream attenuation of inflammatory signal amplification.

Dosage and Administration Information

Administration Protocol: Components

The administration of this conceptual combination is governed by the official instructions established for each component as a monotherapy, as a formal fixed-dose combination product label is not broadly available. Both active ingredients are approved for oral administration.

Benzonatate (Antitussive Component)

Benzonatate is intended for as-needed use, typically administered up to three times a day (TID). The official dose range is 100 mg to 200 mg per single dose, with the total daily intake strictly limited to a maximum of 600 mg. A critical procedural constraint is that Benzonatate capsules must be swallowed whole; they are explicitly prohibited from being broken, chewed, dissolved, or crushed. If a dose is missed, patients are directed to skip the missed dose and resume the regular schedule; doses must not be doubled. Use is approved for individuals 10 years of age and over.

Ambroxol (Mucolytic Component)

Ambroxol typically follows a phased dosing schedule for immediate-release forms. This regimen involves an initial period, often 2 to 3 days, with a higher daily dose (e.g., 90 mg/day), followed by a transition to a lower maintenance dose (e.g., 60 mg/day) taken in BID or TID divided doses. Ambroxol is generally instructed to be taken after meals. Its use is customarily limited to short-term periods, and prolonged administration, such as beyond 4 to 5 days, often requires further medical review. Dose interval adjustments are advised for patients who present with renal or hepatic impairment.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Ambroxol/Benzonatate

The research supporting the fixed-dose combination of Ambroxol and Benzonatate is primarily derived from the individual studies conducted on each component. This overview describes the research landscape for the antitussive action (Benzonatate) and the mucolytic action (Ambroxol), focusing on what the studies explored, the populations involved, and where the current evidence remains limited.

Evidence for Symptomatic Relief of Cough (Antitussive Component)

The antitussive component was studied for its application in research contexts involving outcomes related to physical discomfort (cough). The foundational evidence for this component is derived from initial, small-scale clinical studies that monitored the cough response over defined time intervals.

Research describes that the quality of evidence remains limited and, according to systematic analyses, may not fully align with the methodological standards used in contemporary regulatory evaluation. The evidence is limited regarding the long-term patterns of the antitussive component, and data for certain groups, particularly children under 10 and the geriatric population, remain insufficient.

Evidence for Managing Viscid Mucus and Expectorating Difficulty (Mucolytic Component)

The mucolytic component, Ambroxol, was evaluated in Randomized Controlled Trials (RCTs), systematic reviews, and meta-analyses. Studies explored the component's effects in conditions where symptoms may vary in intensity and are marked by functional limitations related to thick secretions.

Research monitored outcomes linked to functional imbalance, such as the measurement of changes in the sputum property score and patient-reported outcomes describing perceived discomfort related to expectoration. The evidence for the mucolytic action was observed to reflect a pattern of consistency across multiple systematic reviews.

What Research Gaps Remain

The primary gap is the lack of comparative evidence that explores the antitussive component in contemporary trials. Furthermore, specific data evaluating the fixed-dose combination itself, rather than the individual components in isolation, are not widely synthesized in systematic reviews. Long-term effects are not fully established.

Key Studies & References

  1. An overview of efficacy and safety of ambroxol for the treatment of acute and chronic respiratory diseases with a special regard to children
  2. Ambroxol and bromhexine expectorants: safety information to be updated (EMA/CMDh decision)

Frequently Asked Questions (FAQ)

Common questions about Ambroxol/Benzonatate (FAQ)

Q: How quickly does Ambroxol/Benzonatate typically start working?

According to official product information, the antitussive effect of the Benzonatate component generally begins to work fairly quickly, typically within 15 to 20 minutes after taking the dose. This speed of onset relates to its action in the respiratory passages. The action of the Ambroxol component, which helps thin mucus, may have a different, possibly longer, onset time.

Q: How long does the effect of one dose of Ambroxol/Benzonatate last?

Regulatory information indicates that the duration of the cough-relieving effect from the Benzonatate component is usually between 3 to 8 hours per single dose. This is the period during which the medication continues to desensitize the cough receptors. The Ambroxol component works to improve mucus clearance, which is a continuous process.

Q: What are the most commonly reported side effects of taking Ambroxol/Benzonatate?

The most commonly reported side effects across both components include general effects such as drowsiness, headache, and dizziness. Gastrointestinal effects like nausea and constipation are also frequently noted in the official adverse reactions documentation. If you experience any concerning side effects, consult with a healthcare professional.

Q: Is it normal to feel a numbing sensation in the mouth after taking the Benzonatate component?

No, experiencing a numbing or tingling sensation in the mouth, tongue, or throat is not a normal part of the medication's intended use. This is a sign that the Benzonatate capsule has been broken, chewed, or dissolved, releasing the local anesthetic inside the mouth. Due to the risk of serious adverse effects, if this occurs, you should seek immediate medical attention.

Q: What happens if I miss a dose of Ambroxol/Benzonatate?

The general recommendation for the Benzonatate component is to skip the missed dose entirely and resume the regular schedule, without attempting to double up on the dose. For the Ambroxol component, a missed dose should be taken as soon as possible, unless it is almost time for the next scheduled dose. For guidance tailored to your specific circumstances, consult with your pharmacist or prescriber.

Q: Are there any food items that should be avoided while on Ambroxol/Benzonatate?

Ambroxol is generally advised to be taken after meals. Official product information does not specify food restrictions. However, if improper administration of Benzonatate causes oral numbness, regulatory guidance advises refraining from ingesting food or liquids until the numbness has fully resolved to prevent accidental injury.

Q: Is there a risk of addiction or dependency with Ambroxol/Benzonatate?

Regulatory documents classify the Benzonatate component as a non-narcotic antitussive agent. It does not fall under the controlled substance schedules established by governmental authorities. Therefore, a risk of dependence is not associated with this component.

Q: Is it possible to have an allergic reaction to Ambroxol/Benzonatate?

Yes, regulatory documents indicate that the use of this medicine is contraindicated if a person has a known allergy or hypersensitivity to either Ambroxol, Benzonatate, or substances related to local anesthetics. Serious allergic reactions have been reported; if signs of a severe reaction occur, seek immediate medical attention.

Q: Is it safe to use Ambroxol/Benzonatate for a long-term cough (chronic cough)?

The use of the Ambroxol component is generally intended for short-term periods. If a cough persists beyond a few days, a review by a healthcare professional is often required. The Benzonatate component is prescribed for as-needed use to suppress cough. Since the Ambroxol component is generally intended for short-term use, any prolonged administration requires medical review.

Q: Can Ambroxol/Benzonatate cause stomach upset or nausea?

Yes, regulatory documents report that nausea is a common side effect associated with the Ambroxol component. General GI upset or stomach discomfort is also listed as a potential adverse reaction of the Benzonatate component. Consult a healthcare provider if these effects are severe or persistent.

Q: Does Ambroxol/Benzonatate contain any sugar or sweeteners?

While the active ingredients themselves are not sugars, the specific formulation of the dosage form contains various inactive ingredients, or excipients. Official labeling warns that some formulations may contain ingredients that are incompatible with certain rare hereditary conditions, which may relate to sweeteners or sugars present in the product.

Q: Are there any known interactions between Ambroxol/Benzonatate and caffeine?

Official regulatory documents do not list caffeine as a specific drug interaction. However, the Benzonatate component is known to have additive effects with other Central Nervous System (CNS) depressants. It is advisable to discuss any high intake of caffeine with your healthcare provider.

Q: Can Ambroxol/Benzonatate affect a person's heart rate?

While not a common side effect at normal doses, regulatory warnings note that in cases of Benzonatate overdose or severe allergic reactions, serious outcomes such as cardiovascular collapse or cardiac arrest have been reported. If you experience an irregular or rapid heartbeat, you should seek immediate medical attention.

Q: Can this medication cause a dry mouth?

Yes, dry mouth is listed as an Uncommon adverse effect associated with the Ambroxol component in official product safety information. If this effect becomes bothersome, consult with a healthcare professional.

How should Ambroxol/Benzonatate be stored and disposed of?

How to Store and Dispose of Ambroxol/Benzonatate

Storage and disposal must strictly follow regulatory guidance (often based on Benzonatate labeling due to critical safety needs).

Storage Requirements

Condition Requirement
Temperature Store at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F).
Protection Must be protected from light and humidity.
Container Dispense in a tight, light-resistant container.
Safety Must be kept out of the sight and reach of children.

Disposal Instructions

Unused or expired medication should be disposed of via a medication take-back program. If this is unavailable, the product should be mixed with an unpalatable substance (such as dirt or coffee grounds), sealed in a bag, and then placed in the household trash, following official guidance.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Ambroxol/Benzonatate found in:

A-Z Index: